2009 BIO Investor Forum Presenter Profiles

SAN FRANCISCO--(BUSINESS WIRE)--The 2009 BIO Investor Forum takes place Oct. 28 - 29, 2009 at the Palace Hotel in San Francisco, CA.

Business Wire is the official news wire for the 2009 BIO Investor Forum. Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Listed below are 2009 BIO Investor Forum presenter profiles.

Company:	Allon Therapeutics Inc.
Ticker Symbol & Exchange:	TSX:NPC
Investor Relations Contact:	Aaron Keay, Director, IR
Investor Relations Contact Phone:	604-323-6911
Web:	www.allontherapeutics.com
Date of Presentation:	Thursday, October 29, 2009
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and schizophrenia-related cognitive impairment. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer’s disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company’s website: www.allontherapeutics.com.
Company:	Complete Genomics, Inc.
Investor Relations Contact:	Jennifer Turcotte
Investor Relations Contact Phone:	650-943-2846
Web:	http://www.completegenomics.com
Date of Presentation:	Oct. 29, 2009
Founded in 2006, Complete Genomics is a California company that has developed a novel approach to sequencing human DNA that is revolutionizing the human genome sequencing industry. Complete Genomics combines its proprietary third-generation DNA sequencing technology and high-performance computing capabilities to deliver low-cost, high-quality genomic data on an unprecedented scale. The company is currently building the world’s largest human genome sequencing center. This development will allow academic and biopharmaceutical researchers, for the first time, to conduct large-scale complete human genome studies that will help identify the genetic underpinnings of complex diseases and drug responses. For additional information, please visit http://www.completegenomics.com.
Company:	Cyclacel Pharmaceuticals, Inc.
Ticker Symbol & Exchange:	CYCC
Investor Relations Contact:	Corey Sohmer
Investor Relations Contact Phone:	908-517-7330
Web:	www.cyclacel.com
Date of Presentation:	Thursday, October 29, 2009
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of elderly AML, MDS, NSCLC and in Phase 1 in combination with seliciclib. Seliciclib, a CDK inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancers. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. ALIGN markets in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Lozenges for xerostomia.
Company:	ExonHit Therapeutics
Ticker Symbol & Exchange:	ALEHT
Investor Relations Contact:	Corinne HOFF
Investor Relations Contact Phone:	33 1 58 05 47 04
Web:	www.exonhit.com
Date of Presentation:	Wednesday, October 28, 2009
ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player focused on two activities (diagnostics and therapeutics). The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostics and therapies for neurodegenerative indications (particularly Alzheimer's disease) and cancer.
ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.
ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit http://www.exonhit.com.
Company:	Inovio Biomedical
Ticker Symbol & Exchange:	INO
Investor Relations Contact:	Bernie Hertel
Investor Relations Contact Phone:	858-410-3101
Web:	www.inovio.com
Date of Presentation:	October 29, 2009 10:00 a.m.
Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. Its SynCon™ technology enables the design of DNA-based vaccines to protect against known and new, unknown strains of pathogens such as influenza. Inovio’s electroporation-based delivery technology has been shown by initial human data to safely and significantly increase immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Partners include University of Pennsylvania, NIH Vaccine Research Center, Merck, NCI, and HVTN.
Company:	Oncolytics Biotech Inc.
Ticker Symbol & Exchange:	TSX:ONC, NASDAQ:ONCY
Investor Relations Contact:	Cathy Ward
Investor Relations Contact Phone:	403.670.7370
Web:	www.oncolyticsbiotech.com
Date of Presentation:	Wednesday, October 28, 2009
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
Company:	ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange:	ZIOP NASDAQ
Investor Relations Contact:	Tyler Cook
Investor Relations Contact Phone:	617-259-1982
Web:	www.ziopharm.com
Date of Presentation:	10/29/2009
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse, portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous (“IV”) and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world.

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.